Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 6Withdrawn 2Recruiting 2Not yet recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 14Sarcoma 2Other hematologic neoplasm 2Genitourinary 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Nivolumab 7pembrolizumab 4Ipilimumab 4cemiplimab 3relatlimab 2daromun 2Standard of Care 2Prednisone 2Photochemotherapy 2Melphalan 2Interleukin-2 2Dermoscopy 2Cryotherapy 2Carboplatin 2trametinib 1toripalimab 1tirbanibulin 1sulforaphane 1secukinumab 1gadopiclenol 1famitinib 1decitabine and cedazuridine drug combination 1calcipotriene 1anlotinib 1Watchful Waiting 1Vitamin D 1Vincristine 1Toll-Like Receptor 1 1Therapeutics 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Prednisone × Dermatologic × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡